Dysregulation of CBF accompanies AD pathology as indicated by reduced baseline CBF (Bracko et al., 2021), attenuation of autoregulation (Niwa et al., 2002) and impairment of NVC (Niwa et al., 2000; Iadecola, 2017; Mughal et al., 2021). The gene discussed is CEBPZ; the disease is Alzheimer disease.